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The estimated number of new cases of carcinoma of the head and
neck (SCCHN) is over 60 000 per year in Western occidental
countries (Landis et al, 1998). The location of the primary tumour
varies, but the initial treatment remains surgery and/or radio-
therapy if locoregional treatment is appropriate. Despite optimal
treatment, 50% of patients develop locoregional recurrence, often
in irradiated fields, and 30% have metastatic disease (Vokes et al,
1993; Armand et al, 1995).
Patients with recurrent or metastatic disease receive chemo-
therapy, but the objective response rate is about 10–50% for single
agent treatments, with a short response duration ranging from 4 to
6 months. Proven effective drugs in SCCHN are cisplatinum, 5-
fluorouracil (5-FU), methotrexate, bleomycin and more recently
carboplatin and ifosfamide. The new drugs have not radically
changed response rates. Therapeutic options for patients with
incurable recurrent or metastatic disease are limited. Nevertheless,
taxanes may improve results both as single agents and in associa-
tion with other active drugs in SCCHN.
Docetaxel (Taxotere®) is a semisynthetic derivative of 10
deacetyl Baccatin III, an inactive non-cytotoxic precursor
extracted from the European Yew (Bissery et al, 1991). Docetaxel
is obtained after esterification of a side-chain. In vitro studies have
demonstrated docetaxel activity on cell lines and murine or human
tumour xenografts (Riou et al, 1992). Human SCCHN cell lines
have proved to be highly sensitive to docetaxel even in platinum-
refractory disease (Braakhuis et al, 1994). In vitro data indicate
that there is no cross-resistance between docetaxel and 5-FU or
cisplatinum in some cell lines.
Six phase I studies have determined neutropenia as the dose-
limiting toxicity for docetaxel as 1-h infusion (Motti et al, 1992;
Pazdur et al, 1992; Bissett et al, 1993; Burris et al, 1993; Extra et
al, 1993; Tomiak et al, 1994). The recommended dose for phase II
study was 100 mg m–2 as a 1-h infusion, every 3 weeks.
In the phase I studies, objective responses were observed partic-
ularly in squamous cell carcinoma of the lung, head and neck and
the other cancers of squamous origin. These arguments have justi-
fied phase II studies in SCCHN. We report one of these, in a
selected population of patients with measurable metastatic disease.
PATIENTS AND METHODS
Patients were eligible for this study if they had histologically or
cytologically proven SCCHN recurrent after initial treatment,
locally advanced disease with no possibility of curative treatment
by surgery and radiotherapy, or metastatic disease. Undifferentiated
or non-keratinizing carcinoma and all tumours of the nasal and
paranasal cavities or nasopharynx were excluded. Patients were
allowed neoadjuvant chemotherapy prior to locoregional treatment
but not within 12 months before entering the study.
Other criteria were: WHO performance status ≤ 1, adequate bone
marrow, liver and renal functions. Patients with known or sympto-
matic brain or meningeal metastases, symptomatic peripheral
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Correspondence to: J-P Armandneuropathy ³ grade 2 according to the NCI criteria, or other serious
illness or medical conditions were not eligible. Prior or concurrent
treatment with colony-stimulating factors or continuous treatment
with corticosteroids was not allowed. Signed informed consent was
obtained from each patient before entering the study.
All patients had to have measurable lesions, with at least one
diameter ³ 2 cm, or multiple lung metastases with at least one
lesion having two diameters ³ 1 cm. At the Gustave Roussy
Institute only patients with lung metastases were included in order
to have clearly measurable disease. This excluded locoregional
recurrences or locally advanced disease, which have imprecise
limits making evaluation very subjective.
Each course of docetaxel was administered by intravenous (i.v.)
infusion over 1 h, 100 mg m–2 every 21 days. No anti-emetic or
antibiotic prophylaxis was allowed. No systematic premedication
was given to the patients. At the beginning of the study, steroids
were not yet recommended to prevent hypersensitivity reactions
and to decrease peripheral oedema. During the study a standard
premedication was introduced: methylprednisolone 32 mg, orally
12 and 3 h before infusion, at the end of infusion, and 12, 24 and
36 hours after the end of infusion. Seven patients received corti-
costeroid premedication. Docetaxel was to be adjusted on the basis
of toxicities, with dose reductions in patients who experienced
grade 4 haematological toxicities (except grade 4 neutropenia),
and for other grade 3 toxicities including skin, neurological and
nausea/vomiting.
Computerized tomography (CT) scan was chosen as the method
of evaluation as it is more precise and reproducible for the same
lesion than X-rays. The response criteria was based on WHO defi-
nition. Response was defined as follows: complete response (CR),
absence of all clinically and/or radiologically detectable disease;
partial response (PR), greater than 50% reduction in the products
of all measurable disease with no new lesions; stable disease (SD),
less than 25% increase in tumour volume with no new lesions; and
progressive disease (PD), greater than 25% increase in any tumour
volume or the appearance of a new lesion. Evaluations were
performed every 6 weeks.
Toxicity was evaluated according to National Cancer Institute
(NCI) criteria. Patients were evaluated bi-weekly for laboratory
parameters (blood cell counts, serum electrolytes and liver func-
tion tests), and every 3 weeks for clinical tolerance.
The duration of response and the time to progression were
defined as the time elapsed from first administration to first docu-
mented progression or death. Survival was measured from the first
day of treatment to death. All survival functions were computed
using a Kaplan–Meier method (SAS software).
Pharmacokinetic (PK) blood sampling was performed at the
time of first infusion. Blood samples were collected according to
one of the four population pharmacokinetic protocols, summarized
in Table 1.
Docetaxel concentrations were determined by high-perfor-
mance liquid chromatography assay with UV detection at 225 nm.
The method involved a solid-phase extraction step (C2 micro
columns) using the Advanced Automated Sample Processor
(AASP, varian). The extract was then automatically chromo-
tographed on a C-18 reversed phase column. Pharmacokinetic
parameters were estimated by Bayesian estimation using concen-
tration time data for each subject and the previously defined popu-
lation model as prior information. A three-compartment structural
model with first-order elimination was used. Individual PK
analysis was performed using the NON MEN programme. The
analysis focused on docetaxel plasma clearance (CI) and the area
under the curve (AUC) parameters.
RESULTS
All 24 patients were entered into the study between December
1992 and July 1995. The characteristics of the population are
summarized in Table 2. Of 24 patients enrolled and treated in the
study, 21 were evaluable for response and 24 for toxicity. One
patient was not eligible for response, because of insufficient
tumour assessments. Two patients received only one cycle: one of
these discontinued treatment because of renal failure after the first
cycle, the other had skin toxicity related to the drug and was with-
drawn after the first cycle. But all patients were included to calcu-
late the intent to treat response rate. Nineteen patients (79.2%) had
prior surgery and 20 (83.3%) previous radiotherapy at the primary
tumour site. Only four patients had received neo-adjuvant
chemotherapy of 5-FU–cisplatinum. All patients had good perfor-
mance status (WHO criteria 0 or 1). The median age of the
population was 60 years (range 46–69). The median disease-free
interval between the initial diagnosis and first metastasis was 13
months (range 0–32 months). At the date of enrolment, 21 (87.5%)
patients had metastatic disease: 17 had no local relapse and only
metastatic disease, two had primary not excised with metastatic
diffusion, two had locoregional recurrence and metastatic disease.
The most common metastatic site was the lung: 22 patients
(91.7%). All patients were carefully reviewed to differentiate
between metastasis from SCCHN and a primary lung tumour, e.g.
multiple sites of disease. No patients had isolated bone or liver
metastasis. Two patients (8.3%) had only locoregional disease,
with advanced hypopharyngeal primary (one with two synchro-
nous head and neck tumours) with no prior treatment.
A total of 104 cycles were administered with a median of 4.5
per patient (range 1–9). Only one patient had a dose reduction after
the first cycle (75 mg m–2) due to grade IV neutropenia. In this
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Table 1 Pharmacokinetic protocols
PK protocol number Sampling times
Before infusion During infusion After infusion After infusion (h)
I Just before T0 5 min before end 10 min after end 2 h
II Just before T0 30 min after start 20 min 3 h
III Just before T0 5 min before end 30 min 4 h
IV Just before T0 30 min after start 1 hour 5 h
PK = pharmacokinetic.study 6/104 cycles were delayed more than 3 days but fewer than
7 days, and 2/104 cycles were delayed more than 7 days. The
median cumulative dose was 449 mg m–2 (range 99–916) with a
relative dose intensity of 1.00 (range 0.78–1.04). Nine patients
received at least six cycles. Treatment was discontinued because of
toxicity in only two cases: one skin toxicity after the first cycle,
and an association of skin toxicity and oedema after six cycles.
One patient was lost to follow-up after four cycles. Only seven
patients received preventive premedication for peripheral oedema
since it was not systematically prescribed at the first infusion.
Individual pharmacokinetic analysis was performed in 22
patients. They had a mean age of 58.9 years (range 46–69) and a
mean body surface area of 1.71 m2 (range 1.32–2.00). Patients
presented 1–4 quantifiable concentrations with actual sampling
times ranging from 0.5 to 25 h.
The mean clearance in this population was 19.3 1 h–1 m–2
(range 7.7–30.8) and the mean area under the curve (AUC) was
6.00 mg ml–1 h–1 (range 3.28–12.50). The results obtained in this
population with SCCHN were similar to those obtained in 577
patients with various type of tumours (Bruno et al, 1998). This PK
study in a large population shows a mean clearance of 20.81 h–1 m–2.
Of the 24 patients enrolled and treated in the study, all were
included in the efficacy analysis (intent to treat). Five patients had
partial responses (20.8%), four with lung metastases and one with
locally advanced disease. The overall response rate was 20.8%
with 95% CI 7.1–42.2. For all patients the number of cycles given
to obtain a response was two. The median duration of response
was 18.7 weeks with a range (13.1–50.3) (cf Figure 1). The patient
with the longest duration (50.3 weeks) had locally advanced
disease. Median time to progression was 11.7 weeks (range
4.6–52.6). Median survival of the entire population was 6.7
months (range 1.3–24.0). Three of the responders had at
least three metastatic sites involved. None of them had prior
chemotherapy but the number was too small to conclude on this
point. Their profiles and the duration of response respectively are
the following: two patients had synchronous metastasis and
primary tumour (one had a tonsillar and hypopharyngeal tumour
with a cervical lymph node and contralateral supraclavicular
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Table 2 Population characteristics
No of patients treated/eligible 24/23
Median age (range) 60 (46–69)
Sex ratio: male/female 23/1
WHO performance status 0/1 14/10
Prior surgery 19/24
Prior radiotherapy 20/24
Prior chemotherapy 4/24
Metastatic
One site 16/24
Multiple sites 5/24
Locally advanced 2/24 (8.3%)
Unknown 1/24 (4.2%)
Sites of metastasis (n = 21)
Lung 91.7%
Bone 12.5%
Lymph node 12.5%
Pleura 16.7%
Hypopharynx 12.5%
Stage at diagnosis
Stage I 4 (16.7%)
Stage II 2 (8.3%)
Stage III 4 (16.7%)
Stage IV 14 (58.3%)disease (50.3 weeks of response duration); the second had
synchronous mediastinal lymph nodes, lung metastasis, bone
metastasis and primary tumour (16.0 weeks). The other three
responders had: two lung metastases and a right adrenal mass
(18.7 weeks); bilateral lung metastases (13.1 weeks); and lung and
liver metastases with a left pleural effusion (40.5 weeks). For two
patients progressive disease had been observed with the appear-
ance of new lesions (skin metastasis for one and new lung metas-
tasis for the second). The patient with locoregional recurrence
progressed in a local site. The last two patients were withdrawn
from the study despite partial response due to toxicity.
Toxicity
Twenty-four patients were evaluable for toxicity (summarized in
Table 3). Neutropenia was very frequent with an overall incidence
of 95.8% of any grade and a majority of grade IV (79.2% of
patients). However, median duration of neutropenia was short, 4
days (range 1–16), and growth factors were not required. Despite
the high incidence of myelosuppression, there were no instances of
febrile neutropenia, probably because of the short duration. In
addition to haematological toxicity, one patient suffered from
grade 3 infection but not neutropenia at the time. The most
common non-haematological toxicity was skin toxicity (79.2%),
including nail changes, onycholysis and cutaneous reactions. This
toxicity was frequent but mild or moderate. Only one patient
suffered from grade 3/4 (4.2%) skin toxicity. Two patients discon-
tinued treatment due to skin toxicity (one after cycle 1 and the
second after cycle six). Sixteen per cent of the patients suffered
nausea and two patients from vomiting, all with grade 1 or 2. We
observed hypersensitivity reactions in two patients. Two patients
required premedication for subsequent cycles using dexametha-
sone and dexchlorpheniramine (H1 antagonist). They had no
further hypersensitivity reactions. Fluid retention was reported in
45.8% of patients, and one patient discontinued the study due to
fluid retention associated with skin toxicity. The incidence of
moderate/severe fluid retention was 29.2%. Only seven patients
were premedicated for oedema. The median cumulative dose to
onset of fluid retention was 493 mg m–2 and 596 mg m–2 to
moderate/severe. In the absence of premedication, only two
patients had a weight gain of over 10% due to fluid retention.
One patient presented grade 3 neurotoxicity after six cycles of
docetaxel. He had not received prior neurotoxic treatment, particu-
larly cisplatinum. Only one death was related to a drug toxicity:
pulmonary infection without neutropenia. Of 24 patients, all have
subsequently died: 15 from progressive disease after the discontin-
uation of treatment, two from non-drug-related infection (for one
patient, 1 month after the last cycle; for the second, 20 months
after). Two patients died from cardiac disorders: one had a
myocardial infarction at day 7 of cycle 5. He had a history of coro-
nary bypass surgery and myocardial infarction and no relation to
the study was established. For the second, it was unrelated because
he died 85 days after the last cycle of congestive cardiac failure
and he had a previous history of pulmonary embolism and high
blood pressure. Four patients died from other non-drug-related
causes.
The safety profile of docetaxel in this trial is the same as that
observed in other phase II trials.
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Table 3 Toxicity in the 24 patients (worst grade per patient)
Haematotoxicity
Neutropenia any grade 95.8%
grade IV 79.2%
Thrombocytopenia any grade 4.2%
Anaemia grade III 12.5%
Febrile neutropenia 0%
Non-haematotoxicity any grade (grade 3–4)
Skin 75.0% (4.2%)
Alopecia 66.7%
Asthenia (severe) 50% (8.5%)
Fluid retention 45.8%
Incidence moderate/severe 29.2%
Infection 29.2% (4.2%)
Neurosensory 29.2% (4.2%)
Nausea 16.7% (0)
Stomatitis 16.7% (4.2%)
Diarrhoea 12.5% (4.2%)
Vomiting 8.3% (0)
HSR 8.3% (0)
Neuromotor 0 (0)
HSR, hypersensitivity reaction.
Table 4 Patient characteristics in four phase II studies of docetaxel in SCCHN
Catimel Dreyfuss Couteau Fujii
Dose of docetaxel (mg m–2) 100 100 100 60
No. of patients registered 40 31 24 24
No. of patients evaluable for response 37 29 21 22
Histology
Squamous cell carcinoma 40 31 24 17
Adenocarcinoma – – – 1
Others – – – 6
Disease extent
Local ± regional 26 (66%) 26 (84%) 2 (8.7%) Nd
Distant metastases 11 (28%) 3 (10%) 17 (73.9%) Nd
Locoregional + distant metastases 3 (7%) 2 (6%) 4 (17.3%) Nd
Prior therapy
Radiotherapy 32 (82,5%) 31 (100%) 20 (83%) Nd
Surgery 24 (60%) 26 (84%) 19 (79%) Nd
Induction chemotherapy 10 (25%) 10 (32%) 4 (16.6%) 16 (66.6%)
Nd, not done in published paper.DISCUSSION
The response rate in this study is much lower than the published
results (Table 4) of three other studies. However, the selected
population is very different, and this could explain the differences
in results.
In the Japanese study (Fujii et al, 1995), docetaxel was adminis-
tered every 21 or 28 days at a dose of 60 mg m–2. Most impor-
tantly, this study included a mixed patient population: 17 had
squamous cell carcinoma, two had salivary gland cystic adeno-
carcinoma, one had adenocarcinoma, three had undifferentiated
tumours and one had mucinous squamous cell carcinoma. Among
primary sites involved, five patients had nasopharyngeal tumour
and four had a salivary gland primary. If we only take into account
squamous cell carcinoma, the response rate, which was initially
5/22 (22.7%), becomes 2/17 (11%). Dose intensity was low
(administration every 28 days), and the dose used was 60% of the
recommended dose in Europe. However, the pharmacokinetics of
docetaxel are known to be identical in European, American and
Japanese populations (Tanigawara et al, 1996; Bruno et al, 1998).
The two other phase II trials in SCCHN (Catimel et al, 1994a;
Dreyfuss et al, 1996) used the same schedule as ours: 100 mg m–2
every 3 weeks. Once again the populations were different, and this
could explain the higher response rates reported in these studies.
The median response durations reported are consistent (about 6
months) and are comparable to those of other agents used sepa-
rately or in combination.
Dreyfuss reported the results of a phase II study with 31
patients, of which 26 (84%) had advanced recurrent locoregional
disease and three (10%) had metastatic disease, two had both
(6%). As in our study there was a low incidence of peripheral
oedema: five patients (13%). However, dose reduction due to
neutropenia was frequent. The overall response rate was 42%. Of
the 13 responders only one had metastatic disease: 1/13 (7%).
Median response duration was 5 months (range 2–14).
The EORTC study included 43 patients (Catimel et al, 1994a).
Forty were evaluable of whom 26 (66%) had locally advanced or
recurrent disease, 11 (28%) metastatic, three both (7%). In this
series, they did not find a difference in terms of response rate
between the two populations: of patients with locally advanced
disease, 8/25 (32%) had partial responses and 3/11 (27%) of
patients with metastatic disease responded. However, numbers are
rather low for comparison.
For other drugs, most published trials mixed locally advanced or
recurrent disease. The first phase II of paclitaxel in SCCHN was
conducted by the ECOG using a dose of 250 mg m–2 administered
over 24 h with granulocyte-stimulating factors between cycles
(Forastiere et al, 1993). The overall response rate was 40%. Of the
27 patients enrolled, 17 had locoregional disease, six metastatic
and four locoregional with distant diffusion. Ten objective
responses were reported. Only two partial responses were seen in
ten metastatic patients with lung spread. Response duration ranged
from 1 to 5 months. An Ohio University study was proposed with
the same schedule for 28 patients (Smith et al, 1995). No patient
had metastatic disease at inclusion. Patients received three cycles
of chemotherapy, followed by locoregional treatment. The authors
reported an overall response rate of 23% with two complete and
four partial responses, and a median response duration of 6 weeks
to 3 months for the complete response. An Italian trial used a lower
dose of paclitaxel (175 mg m–2, over 3-h intravenous infusion)
given only to patients with locoregional disease; the overall
response rate was 20% without any complete response (Gebbia et
al, 1996). In published trials, vinorelbine gives an overall response
rate of 22% with no complete response (Gebbia et al, 1993b). Five
partial responses were seen in a mixed population with no
metastatic disease (two patients with no prior treatment and locally
advanced disease, two with locoregional recurrence after radio-
therapy and one with lymph node recurrence). Among the
inhibitors of topoisomerase I, Topotecan has a response rate of
22% with a short duration (1–2.5 months) (Robert et al, 1994).
Gemcitabine gave an overall response rate of 13% (7/61) in 61
patients (Catimel et al, 1994b). Three objective responses were
observed in lung metastases. The median duration of response
was 4 months (range 2–8.5). A phase II study of edertrexate
(Schornagel et al, 1992) included 47 patients, of whom 15 (31%)
had metastatic disease. The overall response rate was 5/47 (10.6%)
with a median duration of 17 weeks (range 10–56).
Analysis of these results illustrates the difficulty of comparing
studies even for one single drug. More recent trials have reported
different response rates for the same drug, but this could be due to
the different populations included. In our study, we decided to
include only patients with lung metastasis because it is well known
that SCCHN represents a constellation of tumours with various
sensibilities to chemotherapy, such as laryngeal tumours, oral
cavity primary and others. The evaluation of response rate in
SSCHN can be more homogeneous if the same site of metastatic
disease is chosen as was done in this study.
The other point of discussion for evaluation of a trial is the dura-
tion of response and the time spent on treatment of patients. In
most published studies, including ours, the median duration of
response is 5–6 months (20–24 weeks). Most patients received a
median number of four cycles, then 12 weeks spent on treatment.
For patients with symptomatic disease, time might be spent well
on treatment if it produces a clinical benefit. For the others, partic-
ularly in metastatic disease, the benefit of treatment should be
evaluated in terms of overall survival without treatment rather than
in terms of percentage of response or median duration of response
because the objective is not yet to cure. Evaluation of surrogate or
new end points appear particularly important for the population
with metastatic disease.
The role and the timing of treatment by chemotherapy is not
well established. In our institute we have conducted an analysis of
prognostic factors of response to cisplatinum-based chemotherapy
in SCCHN (Recondo et al, 1991). Patients who had previous
radiation therapy to the primary tumour had less response to
cisplatinum infusion than those with only metastatic diffusion. The
response rate was dependent on the extent of disease.
The expected response rate was 70% for neoadjuvant therapy,
only 5% for a locoregional recurrence and 40% for metastatic
disease. The following factors influenced cisplatinum chemo-
therapy response in univariate analysis: performance status,
weight loss, length of disease-free interval, no bone metastasis,
number of metastatic organs. In multivariate analysis, previous
therapy and local relapse were the major variables which influ-
enced the expected cisplatinum chemotherapy activity.
Taxanes could probably have a better response rate than alkyl-
ating agents in locoregional recurrence in previously irradiated
fields. The difficulties: in reporting and comparing these studies
are variations in tumour biology, adequate demonstration of recur-
rence and demonstrating that the duration of response is equivalent
in relapsed and metastatic disease and is not dependent on the type
of radiotherapy received. A good palliative treatment for local
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reasonable goal (Vokes et al, 1991; Gandia et al, 1993). Results of
a phase II study for new drugs in head and neck cancer could
identify compounds differently active in local and distant relapse.
This phase II study demonstrate that the toxicity of docetaxel in
the population is acceptable with major neutropenia but no febrile
neutropenia. Docetaxel has good activity in this population with
metastatic disease.
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